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Abstract
Introduction: Renal insufficiency (RI) is associated with higher morbidity and mortality in patients (P) with coronary artery
disease and in P submitted to angioplasty. In ST-segment elevation acute myocardial infarction (STEAMI), this impact has not
been well demonstrated. 
Aim: To evaluate the impact of RI in P with STEAMI. 
Methods: We evaluated 160 P admitted with STEAMI, mean age of 62±14 years, 76% male. We determined creatinine levels
on admission. RI was defined as a level >1.5 mg/dl. Analysis of clinical, electrocardiographic and laboratory variables was
performed, in relation to the endpoint defined as the occurrence of death at 30-day follow-up. 
Results: There were 16 deaths (10%) at 30-day follow-up. P with RI (n=21) were older (68±11 vs 61±14 years, p<0.001), more
often had diabetes (57 vs 24 %, p=0.004) and presented more often with Killip class ≥2 (57 vs 12%, p<0.001). The use of statins
(62 vs 83%, p=0.05) and β-blockers (24 vs 65%, p<0.001) was lower in P with RI. Mortality was higher in RI P (62 vs 2%, p<0.001).
The univariate predictors of death were age ≥75 years, diabetes, Killip class ≥2 on admission, RI, non-use of statins and β-blockers
and use of diuretics. In multivariate analysis, independent predictors of death at 30 days were RI (HR 29.6, 95% CI 6.3-139.9,
p<0.001) and non-use of β-blockers (HR 0.13, 95% CI 0.02-1.01, p=0.01). 
Conclusion: In P admitted for STEAMI, the presence of RI was an independent predictor of death at 30 days whereas the
usage of β-blockers was protective. 
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Introduction
Cardiovascular diseases are the leading cause of
death in patients with terminal renal insufficiency
(RI) [1, 2] and are highly prevalent in patients with the
most severe forms of RI [3]. Patients with terminal
renal disease who suffer a myocardial infarction (MI)
have a mortality that reaches 59.3% in the following
year [4, 5]. Those who were submitted to
percutaneous coronary angioplasty have higher rates
of restenosis [6], and survival after coronary artery
bypass grafting is lower than that observed in
patients without renal disease [4]. Chronic renal
disease was associated with a 40% increased risk of
MI, stroke and cardiovascular death among
participants of the Heart Outcome and Prevention
Evaluation (HOPE) study [7]. 
There are few studies in patients with less severe
forms of RI and coronary disease, although this is
a very important population: National Health And
Nutrition Examination Survey III [8] identified 9.74%
of males and 1.78% of females with a creatinine level
≥1.5 mg/dl. In patients with renal disease and acute
MI, the use of aspirin, β-blockers (BB), angiotensin
converting enzyme inhibitors (ACEI), statins and
antagonists of GP IIb/IIIa receptors is lower when
compared with patients with preserved renal
function [8-11]. The Global Registry of Acute Coronary
Kardiologia Polska 2005; 63: 4
374 Ana Teresa Timóteo et al
Events (GRACE) [12] reported that these drugs are
used in respectively 95.3%, 86.2%, 65.6%, 54.3% and
28.1% of patients with normal/mildly impaired renal
function and 92.7%, 64.9%, 62.1%, 31.6% and 14.6%
of patients with severe renal dysfunction (p<0.05 for
each class of drugs). 
Another important point is the absence of an
appropriate characterisation of this high risk population,
since those patients are usually excluded from large
clinical trials. In the last few years, several risk prediction
models have been developed, such as the TIMI risk score
for ST-elevation acute myocardial infarction (STEAMI)
[13]. These scores are derived from large clinical trial
databases, but real-life unselected patient populations
seem to differ from those enrolled in clinical trials. In
fact, those studies seem to under-represent some of the
most important sub-groups of patients, such as the
elderly and patients with RI. 
More recently, two scores were developed for all
acute coronary syndromes, to determine the risk of
in-hospital [14] and 6-month [15] mortality. These
scores are based on a large scale, multinational registry,
with a relatively unselected patient population. The
scores included new variables that are characterised by
a higher predictive capacity, and one of those variables
is renal function [12]. 
Based on the previously mentioned evidence, the
aim of our work was to evaluate the prognostic impact
of RI in patients admitted for STEAMI. 
Methods
This retrospective study included 160 consecutive
patients admitted to our Intensive Care Unit for
STEAMI (January – December 2002). STEAMI was
defined as the presence of ST-segment elevation in the
ECG and the presence of angina for at least a 30-
minute duration or elevation of CK-MB levels above
the upper normal limit. 
The data were obtained from hospital clinical
records and when follow-up information did not cover
30 days, a telephone call was made to each patient.
Patients were divided into two groups: with or without
RI, defined by a serum creatinine level on admission
≥1.5 mg/dl. We evaluated the patient's basal clinical
variables: demographic, risk factors, previous coronary
artery disease, presence of heart failure on admission
(Killip-Kimbal class), medication, infarct location and
reperfusion technique.
Using multivariable analysis models, we determined
the impact of clinical, demographic and angiographic
variables on a 30-day prognosis, defined by the
occurrence of death. 
In a secondary analysis, we obtained corrected
creatinine clearance (corrCrCl) for age and gender,
using the Cockcroft-Gault formula [16]: 
corrCrClmale= (140-age)/Cr x 72 x body mass [kg]
corrCrClfemale=0.85 x corrCrClmale
Patients were divided into four groups according to
corrCrCl levels: normal renal function, with corrCrCl ≥90
ml/min (n=44); mild RI with corrCrCl between 60 and
89 ml/min (n=66); moderate RI with corrCrCl between
30 and 59 ml/min (n=45); severe RI with corrCrCl
<30ml/min (n=6). 
Statistical analysis
Categorical variables were expressed as frequency
and respective percentage and were compared by the
Chi-square test with Yates correction. Continuous
variables were expressed as mean ± standard deviation
and compared using Student's t-test. The survival analysis
was performed using Kaplan-Meier curves and by the
Log-rank test. By using Cox regression models, which
included all variables with potential statistical significance
by univariate analysis (p<0.10), we identified independent
predictors of outcome. We regarded results with p<0.05 as
statistically significant. The statistical analysis was
performed using SPSS version 10.0 (Chicago, Illinois). 
Results
Of 160 patients studied, 76% were males. The mean
age was 62±14 years. No patient was on a dialysis
programme. The group with RI (13% of patients) was
slightly older, and had a higher prevalence of diabetes
(Table I). Heart failure signs on admission were also
more prevalent in the group with RI. There were no
differences in the previous history of coronary disease,
remaining risk factors, coronary angiography results or
reperfusion technique. BB and statins were less often
used in the group with RI. On the other hand, diuretics
were more often prescribed. At 30-day follow-up,
mortality was 2% in patients with normal function and
62% in patients with RI (p<0.001). 
In univariate analysis, the presence of RI was one of
the strongest predictors of outcome (RR 23.8, 95% CI
7.48-75.6) (Table II), with a clear and early separation of
survival curves (Log-rank, p<0.001) (Figure 1). When
analysing the different levels of corrCrCl, we found that
the group with severely compromised renal function
had the worst outcome, although moderate RI also had
implications on outcome (Figures 2, 3 and 4). 
In multivariate analysis, the only independent
predictor of outcome was RI (HR 29.6; 95% CI 6.3-139.9;
p<0.001) (Figure 5). On the other hand, BB use had
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independent protective effects on outcome in this
population (HR 0.13; 95% CI, 0.02-1.01, p=0.05). 
Discussion
Coronary artery disease is highly prevalent among
patients with renal disease, even in less severe stages [3,
7]. The prevalence of renal disease, meanwhile, is
increasing in the general population, reaching almost 10%,
particularly in males [8]. We may consider it an important
public health problem, particularly due to the ominous
associated prognosis [4-6]. In patient populations
admitted because of acute MI, the percentage of patients
with RI varies from 17% to 35% [11, 17-18]. 
Our study demonstrated that a significant
proportion of patients (13%) presenting with STEAMI
have abnormal renal function, as well as more adverse
basal clinical conditions (particularly the presence of
diabetes and heart failure signs on admission). Other
authors have already recognised the greater risk of
adverse events in patients with chronic RI, such as the
case of the HOPE study [7], but the majority of papers
on RI and coronary artery disease delt with advanced
RI in dialysis patients. In this population, Herzog et al.
[5] observed a bad outcome in the course of acute MI,
with a survival rate of only 41% in the first year and
27% at two-year follow-up. Less severe stages also
have a negative impact on survival after surgical
revascularisation [19, 20]. 
Recently, in the GRACE registry, it was validated
that serum creatinine on admission is a useful
prognostic predictor in patients with acute coronary
syndrome [13-15]. Previously, this variable was not
considered a predictor, mainly due to the fact that
patients with RI were frequently under-represented in
large clinical trials. 
In our study, RI (defined as serum creatinine on
admission ≥1.5 mg/dl, to avoid other variables that
might confound this value, particularly the occurrence of
(%) Without With p
RI=139 RI=21
Age (years) 61±14 69±11 <0.001
Male gender 77 67 NS
Risk factors
Hypertension 54 71 NS
Smoking 42 33 NS
Diabetes 24 57 0.004
Hyperlipidemia 50 33 NS
Previous history
AMI 9 19 NS
PCI 2 5 NS
CABG 2 5 NS
Anterior location 50 57 NS
Killip class ≥2 12 57 <0.001
Thrombolysis 24 24 NS
Coronary angiography 91 86 NS
Multivessel disease 45 52 NS
PCI 72 62 NS
Medication
ACEI 78 71 NS
BB 65 24 <0.001
Statin 83 62 0.05
Abciximab 60 43 NS
Diuretic 21 81 <0.001
Death at 30 days 2 62 <0.001
Table I. Population characteristics
Abbreviations: RI-renal failure; AMI – acute myocardial infarction;
PCI – percutaneous coronary interventions; CABG – coronary
artery bypass grafting; ACEI – angiotensin converting enzyme
inhibitors; BB – β-blockers
Relative risk (CI 95%) P (Log-rank) 
Age ≥75 years 3.59 (1.45-8.89) 0.003
Diabetes 5.43 (2.00-14.76) 0.0002
Killip class ≥2 9.97 (3.75-26.5) <0.001
Creatinine ≥1.5 mg/dl 23.8 (7.48-75.56) <0.001
Statins 0.42 (0.16-1.07) 0.06
BB 0.05 (0.006-0.35) <0.001
Diuretics 16.84 (3.98-71.31) <0.001
Abciximab 0.44 (0.17-1.15) 0.09
Table II. Univariate analysis

























Figure 1. Survival curve for the occurence of
death at 30-day follow-up
days
Kardiologia Polska 2005; 63: 4
contrast nephropathy) was an important predictor of
outcome, as well as age, the presence of diabetes and
the presence of heart failure on admission, although
after multivariate analysis the only factor that remained
as an independent predictor of outcome was RI, showing
its important influence. Also the use of medication,
particularly BB, was associated with an impact on
prognosis, but as a protector, independently associated
with a lower risk of death, in a similar way as described
in the CAPRICORN trial [21]. As for other drugs, this effect
was not as significant, maybe due to the small number
of patients and short follow-up duration. Statins also
had some benefit, but non-significant. The use of several
drugs with a demonstrated effect on outcome, namely
aspirin, BB, ACEI and GP IIb/IIIa receptor antagonists, is
usually lower in patients with renal failure [9-11]. Also in
our population we reported this fact. The lower use of GP
IIb/IIIa receptor antagonist may be due to the reported
increased incidence of haemorrhagic complications
described in RI patients undergoing primary angioplasty
for acute MI [22]. However, in fact, the rise in bleeding
risk occurs in all patients, with only a trend towards an
interaction between creatinine clearance and major
bleeding with abciximab (OR 1.18; p=0.06) and no
interaction with minor bleeding [23]. Abciximab is the
preferred molecule in the context of primary angioplasty
for STEAMI and also the only agent for which clinical
data support safety in patients with chronic RI [24].
Therefore, we believe that there is no justification for
a dose adjustment in RI patients. 
Primary angioplasty was the most often used
reperfusion treatment in our study. Elective angioplasty,
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Figure 3. Occurence of death according to
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Figure 4. Survival analysis according to renal
insufficiency grade (CorrCrCl < and ≥60)
Figure 5. Multivariate analysis for the occurence
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29.6   6.3-139.9    <0.001
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as such, has a higher rate of complications in patients
with RI, particularly with respect to restenosis [6-7, 25].
Also, in the context of primary angioplasty, there is
a significant increase in mortality, haemorrhage and
restenosis [18]. Either the lower use of drugs, or the
worse prognosis associated with myocardial
revascularisation procedures in patients with RI, could
have contributed to the results found in our population. 
In our study, we identified a significant and gradual
increase in mortality risk for each stage of RI,
suggesting that the clinician should be alert to the
presence of RI, due to the higher risk of death. This
supports a more aggressive therapeutic approach, with
the hope of optimising results, which are still
unsatisfactory in patients with RI. 
Conclusions
In patients admitted with STEAMI, the presence of RI
is an independent predictor of death at 30-day follow-up.
The use of BB, in this population, was particularly
important, due to their protective effects against death. 
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Streszczenie
Wprowadzenie: Niewydolnoœæ nerek (NN) wi¹¿e siê z wiêksz¹ czêstoœci¹ zachorowañ i zgonów u pacjentów z chorob¹ wieñcow¹
oraz poddawanych angioplastyce. Natomiast jej wp³yw na rokowanie w przypadku ostrego zawa³u miêœnia sercowego z uniesieniem
ST (STEMI) jest s³abiej udokumentowany. Celem naszego badania by³a ocena wp³ywu NN na rokowanie chorych z STEMI. 
Metody: Ocenie poddaliœmy grupê 160 chorych hospitalizowanych z powodu STEMI w wieku œrednio 62±14 lat, z czego 76%
stanowili mê¿czyŸni. Pomiaru stê¿enia kreatyniny dokonywano przy przyjêciu, a za kryterium rozpoznania NN przyjêto stê¿enie
≥1,5 mg/dl. W odniesieniu do zdefiniowanego punktu koñcowego oceny analizowano charakterystykê kliniczn¹, parametry
elektrokardiograficzne i laboratoryjne oraz umieralnoœæ w okresie 30-dniowej obserwacji. 
Wyniki: W okresie 30 dni zmar³o 16 (10%) chorych. Pacjenci z NN (n=21) byli starsi (68±11 vs 61±14 lat, p<0,001), czêœciej
cierpieli na cukrzycê (57 vs 24 %, p=0,004) oraz byli klasyfikowani w ≥2 klasie wg Killipa (57 vs 12%, p<0,001). Osoby z NN rzadziej
otrzymywa³y statyny (62 vs 83%, p=0,05) i β-adrenolityki (24 vs 65%, p<0,001). Umieralnoœæ w grupie chorych z NN by³a wiêksza
(62 vs 2%, p<0,001). Analiza jednoczynnikowa wykaza³a, ¿e czynnikiem prognostycznym zgonu jest wiek ≥75 lat, obecnoœæ
cukrzycy, klasa ≥2 wg Killipa przy przyjêciu, NN, zaniechanie stosowania statyn i β-adrenolityków oraz stosowanie leków
moczopêdnych. Niezale¿nymi czynnikami rokowniczymi w analizie wieloczynnikowej okaza³y siê: NN (HR 29,6, 95% CI 6,3–139,9,
p<0,001) oraz stosowanie β-adrenolityków, zmniejszaj¹ce zagro¿enie zgonem w tej populacji (HR 0,13, 95% CI 0,02–1,01, p=0,01). 
Wnioski: U chorych hospitalizowanych z powodu STEMI niewydolnoœæ nerek jest niezale¿nym czynnikiem rokowniczym
zgonu w okresie pierwszych 30 dni, natomiast β-adrenolityki wywieraj¹ wp³yw ochronny. 
S³owa kluczowe: ostry zawa³ miêœnia sercowego z uniesieniem ST, niewydolnoœæ nerek, rokowanie
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